Home ETF List About

Portfolio Holdings Detail for ISIN IE00B14X4M10
Stock Name / FundiShares MSCI North America UCITS ETF USD (Dist) USD
IssuerBlackrock
Entity holding fund iShares Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300YDM1GFZR5B4U80
ETF TickerIDNA(USD) LSE
ETF TickerIQQN(EUR) F
ETF TickerIDNA.LS(USD) CXE
ETF TickerINAA.LS(GBX) CXE
ETF TickerINAA.MI(EUR) CXE
ETF TickerINAAz(USD) CXE
ETF TickerIQQN.DE(EUR) CXE
ETF TickerINAA(EUR) ETF Plus
ETF TickerIDNA.L(GBP) LSE

Holdings detail for INCY

Stock NameIncyte Corporation
TickerINCY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45337C1027
LEI549300Z4WN6JVZ3T4680

Show aggregate INCY holdings

News associated with INCY

Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $84.18, changing hands for $84.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-09-18 08:17:02
Incyte Reports Encouraging 24-Week Results From Phase 3 STOP-HS Program Of Povorcitinib
(RTTNews) - Incyte Corporation (INCY) on Wednesday announced encouraging 24-week data from the pivotal Phase 3 STOP-HS program evaluating povorcitinib in adults with hidradenitis suppurativa (HS). - 2025-09-17 03:26:09
Incyte Corporation (NASDAQ:INCY) Short Interest Update
Incyte Corporation (NASDAQ:INCY – Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 9,600,000 shares, an increase of 29.4% from the July 31st total of 7,420,000 shares. Based on an average trading volume of 1,860,000 shares, the […] - 2025-09-11 04:51:36
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Incyte Corporation (NASDAQ:INCY – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eighteen analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating on the company. The […] - 2025-08-26 02:32:54
Incyte (NASDAQ:INCY) Given New $73.00 Price Target at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Free Report) had its price objective increased by JPMorgan Chase & Co. from $67.00 to $73.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. A number of other research firms also recently commented on INCY. Citigroup upped their price objective on […] - 2025-08-25 03:08:46
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Charles Schwab Investment Management Inc. Purchases 38,962 Shares of Incyte Corporation (NASDAQ:INCY)
Charles Schwab Investment Management Inc. raised its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 2.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,682,029 shares of the biopharmaceutical company’s stock after purchasing an additional 38,962 […] - 2025-08-13 05:43:01
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Citigroup Raises Incyte (NASDAQ:INCY) Price Target to $103.00
Incyte (NASDAQ:INCY – Get Free Report) had its price objective lifted by equities researchers at Citigroup from $88.00 to $103.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price suggests a potential upside of 37.54% from the […] - 2025-08-01 04:32:55
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Incyte Corporation (NASDAQ:INCY – Get Free Report) have earned a consensus rating of “Hold” from the eighteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and five have assigned a buy recommendation to the […] - 2025-08-01 03:04:43
Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $76.09, changing hands for $77.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-07-30 10:12:59
Mutual of America Capital Management LLC Sells 478 Shares of Incyte Corporation (NASDAQ:INCY)
Mutual of America Capital Management LLC lessened its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,719 shares of the biopharmaceutical company’s stock after selling 478 shares during the quarter. […] - 2025-07-22 08:02:58
Incyte Corporation (NASDAQ:INCY) Shares Sold by Ballentine Partners LLC
Ballentine Partners LLC trimmed its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 12.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,686 shares of the biopharmaceutical company’s stock after selling 649 shares during the quarter. Ballentine Partners LLC’s holdings in Incyte were worth $284,000 at the end of the most recent […] - 2025-07-17 05:12:56
Cerity Partners LLC Has $8.04 Million Stock Position in Incyte Corporation (NASDAQ:INCY)
Cerity Partners LLC lifted its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 103.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,703 shares of the biopharmaceutical company’s stock after buying an additional 67,495 shares during the period. Cerity Partners LLC owned […] - 2025-07-16 05:40:51
Incyte (NASDAQ:INCY) Price Target Cut to $67.00 by Analysts at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Get Free Report) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $68.00 to $67.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of […] - 2025-07-16 04:26:52
Sheila A. Denton Sells 599 Shares of Incyte Corporation (NASDAQ:INCY) Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $68.61, for a total value of $41,097.39. Following the completion of the sale, the executive vice president owned 26,504 […] - 2025-07-09 06:12:52
Incyte Corporation (NASDAQ:INCY) EVP Barry P. Flannelly Sells 10,903 Shares of Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Barry P. Flannelly sold 10,903 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $743,039.45. Following the sale, the executive vice president directly owned 39,744 shares of the […] - 2025-07-08 06:54:44
Incyte Corporation (NASDAQ:INCY) EVP Sells $587,248.55 in Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Vijay K. Iyengar sold 8,617 shares of the company’s stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $68.15, for a total transaction of $587,248.55. Following the completion of the sale, the executive vice president directly owned 37,701 shares […] - 2025-07-08 06:20:54
Incyte Corporation (NASDAQ:INCY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. trimmed its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 16.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 7,875 shares of the biopharmaceutical company’s stock after selling 1,592 shares during the quarter. Vontobel Holding Ltd.’s holdings in Incyte were worth $477,000 as of its most recent filing […] - 2025-07-08 04:46:50
Sumitomo Mitsui Trust Group Inc. Purchases 25,844 Shares of Incyte Corporation (NASDAQ:INCY)
Sumitomo Mitsui Trust Group Inc. increased its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 473,186 shares of the biopharmaceutical company’s stock after purchasing an additional 25,844 shares […] - 2025-07-03 05:25:07
Incyte Corporation (NASDAQ:INCY) Shares Purchased by Chevy Chase Trust Holdings LLC
Chevy Chase Trust Holdings LLC raised its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 0.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,241 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the quarter. […] - 2025-06-27 05:36:52
Janney Montgomery Scott LLC Boosts Stock Position in Incyte Corporation (NASDAQ:INCY)
Janney Montgomery Scott LLC grew its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 10.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 29,793 shares of the biopharmaceutical company’s stock after purchasing an additional 2,746 shares during the period. Janney Montgomery Scott LLC’s holdings in Incyte were worth $1,804,000 as of its […] - 2025-06-27 04:26:49
State of Alaska Department of Revenue Purchases 590 Shares of Incyte Corporation (NASDAQ:INCY)
State of Alaska Department of Revenue lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 3.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,824 shares of the biopharmaceutical company’s stock after acquiring an additional 590 shares […] - 2025-06-26 05:56:50
Kentucky Retirement Systems Insurance Trust Fund Makes New Investment in Incyte Corporation (NASDAQ:INCY)
Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,624 shares of the biopharmaceutical company’s stock, valued at approximately $280,000. A number […] - 2025-06-26 05:03:09
Incyte Corporation (NASDAQ:INCY) Shares Acquired by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 66.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 79,735 shares of the biopharmaceutical company’s stock after acquiring an additional 31,851 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Incyte were worth $4,828,000 […] - 2025-06-26 04:30:52
Assenagon Asset Management S.A. Has $536,000 Stock Position in Incyte Corporation (NASDAQ:INCY)
Assenagon Asset Management S.A. raised its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 37.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,846 shares of the biopharmaceutical company’s stock after acquiring an additional 2,418 shares during the period. […] - 2025-06-20 04:54:50
Incyte Corporation (NASDAQ:INCY) Shares Sold by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC lowered its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 41.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,117 shares of the biopharmaceutical company’s stock after selling 12,867 shares during the period. Exchange Traded Concepts […] - 2025-06-19 05:43:03
Fifth Third Bancorp Has $551,000 Holdings in Incyte Corporation (NASDAQ:INCY)
Fifth Third Bancorp raised its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 9,103 shares of the biopharmaceutical company’s stock after acquiring an additional 179 shares during the quarter. Fifth Third Bancorp’s holdings in Incyte were worth $551,000 at the end of […] - 2025-06-18 04:56:49
Incyte (NASDAQ:INCY) Raised to “Buy” at Stifel Nicolaus
Incyte (NASDAQ:INCY – Get Free Report) was upgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued on Monday, MarketBeat reports. The brokerage currently has a $107.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $75.00. Stifel Nicolaus’ price […] - 2025-06-18 02:22:54
Stocks Settle Higher on Possible De-Escalation of Israel-Iran War
The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.94%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.42%. June E-mini S&P futures (ESM25 ) are up +1.00%, and June E-mini Nasdaq futures... - 2025-06-17 13:23:43

iShares MSCI North America UCITS ETF USD (Dist) USD INCY holdings

DateNumber of INCY Shares HeldBase Market Value of INCY SharesLocal Market Value of INCY SharesChange in INCY Shares HeldChange in INCY Base ValueCurrent Price per INCY Share HeldPrevious Price per INCY Share Held
2025-11-11 (Tuesday)3,852USD 416,632USD 416,632
2025-11-06 (Thursday)3,852INCY holding decreased by -25USD 405,230INCY holding increased by 6209USD 405,230-25USD 6,209 USD 105.2 USD 102.92
2025-11-04 (Tuesday)3,877USD 399,021INCY holding increased by 5234USD 399,0210USD 5,234 USD 102.92 USD 101.57
2025-11-03 (Monday)3,877INCY holding decreased by -25USD 393,787INCY holding increased by 29028USD 393,787-25USD 29,028 USD 101.57 USD 93.48
2025-10-31 (Friday)3,902USD 364,759INCY holding increased by 7141USD 364,7590USD 7,141 USD 93.48 USD 91.6499
2025-10-28 (Tuesday)3,902USD 357,618INCY holding increased by 1443USD 357,6180USD 1,443 USD 91.6499 USD 91.2801
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of INCY by Blackrock for IE00B14X4M10

Show aggregate share trades of INCY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-06SELL-25106.430103.075 103.410USD -2,585 70.09 Loss of -833 on sale
2025-11-03SELL-25101.79091.160 92.223USD -2,306 69.75 Loss of -562 on sale
2025-10-15SELL-5288.15088.490 88.456USD -4,600 68.97 Loss of -1,013 on sale
2025-10-02SELL-2586.28088.660 88.422USD -2,211 68.78 Loss of -491 on sale
2025-07-29BUY5277.38077.870 77.821USD 4,047 67.71
2025-06-26SELL-5070.81071.500 71.431USD -3,572 67.51 Loss of -196 on sale
2025-06-23SELL-2567.26068.780 68.628USD -1,716 67.50 Loss of -28 on sale
2025-06-17SELL-2568.81070.890 70.682USD -1,767 67.48 Loss of -80 on sale
2025-06-13SELL-2567.75068.960 68.839USD -1,721 67.45 Loss of -35 on sale
2025-06-10SELL-5070.07070.980 70.889USD -3,544 67.41 Loss of -174 on sale
2025-06-05SELL-2567.24067.870 67.807USD -1,695 67.38 Loss of -11 on sale
2025-06-04BUY2467.42068.450 68.347USD 1,640 67.38
2025-05-28BUY47564.93065.610 65.542USD 31,132 67.45
2025-05-20SELL-7565.30066.110 66.029USD -4,952 67.59 Profit of 117 on sale
2025-05-15BUY2562.76062.990 62.967USD 1,574 67.71
2025-05-13SELL-2560.81061.150 61.116USD -1,528 67.83 Profit of 168 on sale
2025-04-22SELL-2557.38058.040 57.974USD -1,449 69.05 Profit of 277 on sale
2025-03-10SELL-2571.13071.890 71.814USD -1,795 72.67 Profit of 21 on sale
2025-03-07SELL-4870.79072.810 72.608USD -3,485 72.70 Profit of 4 on sale
2025-03-05SELL-24069.81069.970 69.954USD -16,789 72.75 Profit of 670 on sale
2025-03-04SELL-7269.68070.000 69.968USD -5,038 72.80 Profit of 204 on sale
2025-02-26SELL-2574.30075.310 75.209USD -1,880 72.79 Loss of -60 on sale
2025-02-21BUY2572.11072.970 72.884USD 1,822 72.76
2025-01-02BUY12169.53070.270 70.196USD 8,494 73.33
2024-12-06BUY5075.92076.460 76.406USD 3,820 73.31
2024-12-02BUY5073.24074.700 74.554USD 3,728 73.25
2024-11-29SELL-5074.59076.080 75.931USD -3,797 73.20 Loss of -137 on sale
2024-11-12BUY10080.58082.020 81.876USD 8,188 72.63
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of INCY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19321,923395451,11071.4%
2025-09-18244,9471,423469,74752.1%
2025-09-17277,858779546,95350.8%
2025-09-16359,781946576,37962.4%
2025-09-15347,4534582,22859.7%
2025-09-12353,0400631,53455.9%
2025-09-11448,7333,894739,70160.7%
2025-09-10490,727248671,93273.0%
2025-09-09515,3951,822682,79175.5%
2025-09-08308,184119479,82864.2%
2025-09-05256,7192,505512,04950.1%
2025-09-04422,6241,507834,71750.6%
2025-09-03381,6797,777624,92261.1%
2025-09-02547,12015,396816,26767.0%
2025-08-29148,294262304,42748.7%
2025-08-28164,0080347,48047.2%
2025-08-27248,926453513,40148.5%
2025-08-26365,1306709,32051.5%
2025-08-25478,1301,306642,31974.4%
2025-08-22344,3522,023596,30157.7%
2025-08-21198,7294,881335,30159.3%
2025-08-20351,6993,977555,34563.3%
2025-08-19343,1103,146574,32859.7%
2025-08-18366,1244,996653,10356.1%
2025-08-15480,8858,035625,79776.8%
2025-08-14593,55436,654806,06873.6%
2025-08-13845,18198,1601,257,50367.2%
2025-08-12462,89642,208678,68968.2%
2025-08-11385,211696595,89264.6%
2025-08-08248,925738426,18758.4%
2025-08-07268,864929420,48663.9%
2025-08-06554,642891731,48475.8%
2025-08-05361,6872,092623,87958.0%
2025-08-04338,0051,464519,15065.1%
2025-08-01414,814828572,87972.4%
2025-07-31570,8456,148777,41773.4%
2025-07-30471,30314,166881,19453.5%
2025-07-29966,64010,5811,593,70160.7%
2025-07-28382,23662625,51061.1%
2025-07-25216,96749422,99051.3%
2025-07-24348,27623528,51765.9%
2025-07-23297,903583487,29761.1%
2025-07-22267,987172446,48960.0%
2025-07-21223,626380406,72955.0%
2025-07-18241,218108471,58951.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.